News for Sanofi Stock (SNY)

Press Release: Availability of the Q2 2024 Aide-mémoire

GlobeNewsWire • 06/25/24

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee

GlobeNewsWire • 06/21/24

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

GlobeNewsWire • 06/21/24

Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule Therapeutics for Immunological Diseases

GlobeNewsWire • 06/18/24

Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting

Seeking Alpha • 06/16/24

Sanofi: A Leader In Life-Saving Vaccines And Treatments

Seeking Alpha • 06/14/24

Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks

Investors Business Daily • 06/13/24

A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge

The Motley Fool • 06/12/24

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

GlobeNewsWire • 06/03/24

3 Dividend Stocks to Buy in June 2024 for Dependable Dividend Growth

InvestorPlace • 06/03/24

FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD

Zacks Investment Research • 05/31/24

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

GlobeNewsWire • 05/31/24

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'

Reuters • 05/31/24

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewsWire • 05/31/24

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

GlobeNewsWire • 05/31/24

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

GlobeNewsWire • 05/30/24

Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

Zacks Investment Research • 05/27/24

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

GlobeNewsWire • 05/27/24

Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million

Reuters • 05/22/24

Sanofi (SNY) Signs Deal for AI-Powered Drug Development

Zacks Investment Research • 05/21/24

Sanofi partners with OpenAI, Formation Bio on AI-driven drug development

Reuters • 05/21/24

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewsWire • 05/21/24

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

GlobeNewsWire • 05/20/24

Shah Capital ends campaign against Novavax board after Sanofi deal

Reuters • 05/20/24

Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker

CNBC • 05/13/24